Back to search results

Adapted CBT-I for Adolescents With Insomnia: The DREAM-IT Study

This study, called DREAM-IT, is testing an adapted version of Cognitive Behavioral Therapy for Insomnia (CBT-I) for teenagers. CBT-I is a type of talk therapy that has been very helpful for adults with insomnia, and some studies suggest it can help teens too. Researchers worked with teens, parents, and healthcare providers to make changes to CBT-I so it better fits teen biology and lifestyles. The study wants to see if this adapted therapy, called Teen CBT-I, improves insomnia symptoms in teens. It also wants to find out if teens and their parents find Teen CBT-I to be acceptable. The study plans to enroll 28 adolescents aged 13 to 18 who have chronic insomnia.

Study design
This study will involve 28 adolescents with insomnia who will be randomly assigned to either receive Teen CBT-I or be placed on a waitlist. Researchers will compare the results between these two groups.
What's involved
Teen-reported insomnia severity will be measured at the beginning of the study, after about 8 weeks of treatment, and again 2 months later. Teen-reported treatment acceptability will be measured after about 8 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 2 months after their treatment to assess their insomnia symptoms.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06541886

Adapted CBT-I for Adolescents With Insomnia : The DREAM-IT Study

Recruiting
NAAges 13–18InterventionalTreatment
Indiana University
~28 participants
Updated 2026-06-04 on ClinicalTrials.gov
What's tested:Cognitive Behavioral Therapy for Insomnia (CBT-I)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Teen-reported insomnia severity
Measured over Baseline, Post-treatment (approximately 8 weeks after baseline), and 2 month follow up
+1 more outcome measured

Conditions

Insomnia

Explore related trials

Insomnia

Where it's being run

1 sites across 1 states
Indiana1

Study leadership

  • Sarah M Honaker, PhD · PRINCIPAL_INVESTIGATOR · Indiana University

Who to contact

Maureen E McQuillan, PhD
[email protected]
317-944-7368
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adolescents (13-18 years) who are in either middle school or high school and meet ICSD-3 diagnostic criteria for Chronic Insomnia Disorder, currently or in the past year, based on self-reported insomnia symptoms, using a screening checklist.
Reside in a state where Dr. McQuillan (supervising provider) is licensed to practice psychology (with PsyPact) which are the following states: Alabama, Arizona, Arkansas, Colorado, Commonwealth of the Northern Mariana Islands, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kentucky, Maine, Maryland, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.
Sufficient English language proficiency for consent and study participation
Reliable internet access to attend virtual visits with audio and video
Parents or other caregivers of these adolescents (hereafter referred to as a parent) must live in the home with the identified adolescent at least 50% of the time and must report playing a parental role for that adolescent. The parent must also be able to attend the final 10 minutes of each treatment session, if the teen is randomized to a treatment condition.

Exclusion

Sleep aid use that is either inconsistent (e.g., used some but not all nights) and cannot be discontinued OR consistent and effective enough that the teen no longer has insomnia symptoms while using it. If a teen agrees to keep the dose and frequency of sleep aid use consistent throughout the treatment and still has insomnia symptoms at baseline, they are not ineligible.
Prior participation in Aim 1 of DREAM IT study (e.g., participation in an Aim 1 focus group).
Comorbid medical or psychiatric conditions, including substance use disorders, that are acute, unstable, or untreated. Individuals with Autism Spectrum Disorder, Epilepsy, Schizophrenia, and Bipolar Disorder will be excluded.
Comorbid delayed sleep wake phase disorder or other active/untreated sleep disorders, including RLS, OSA, and Nightmare disorder
Active suicidal ideation with plan and intent

What this trial measures

  • Teen-reported insomnia severityBaseline, Post-treatment (approximately 8 weeks after baseline), and 2 month follow up

    assessed via the PROMIS (Patient-Reported Outcomes Measurement Information System) sleep disturbance scale, which has been established as reliable and valid with adolescents. Possible scores on this scale range from 10 - 50, where higher scores reflect more severe insomnia.

  • Teen-reported treatment acceptabilityPost-treatment (approximately 8 weeks after baseline)

    based on the widely used Client Satisfaction Questionnaire, which assesses treatment feasibility, satisfaction, and perceived helpfulness. Possible scores on this scale range from 8-40, where higher scores reflect higher acceptability ratings.